Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;9(4):317-327.
doi: 10.1093/nop/npac025. eCollection 2022 Aug.

Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions

Affiliations

Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions

Kristin A Waite et al. Neurooncol Pract. .

Abstract

Background: The Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping model based on the World Health Organization (WHO) classifications to group records for clinically relevant statistical reporting. Newly identified genetic markers more accurately stratify patients than histology alone and were incorporated into the 2016 update to the WHO Classification.

Methods: CBTRUS and consulting neuropathologists reviewed and aligned histology groupings with the 2016 WHO update. "Obsolete" (terms not currently in use) histology nomenclature along with their International Classification of Disease, Oncology 3rd edition (ICD-O-3) codes were identified, some histologies were reclassified to 2016 WHO, and new codes found in 2016 WHO were incorporated. An evaluation of the frequency of histology codes affected in the realignment process, and incidence and survival pre- and post-realignment was conducted.

Results: After review, 67 codes were noted as obsolete, 51 codes were reclassified, and 12 new codes were incorporated. Histology groups most affected were mesenchymal tumors and neuronal/mixed neuronal-glial tumors. Reorganization resulted in 2588 (0.65%) cases with grouping reassignment or reporting change, indicating that the 2016 WHO Classification revision has impacted the collection and reporting of primary brain and other CNS tumors.

Conclusion: This work demonstrates the need to be responsive to changes in classification and coding in order to ensure the most up-to-date and accurate statistics for brain and CNS tumors. This will require collaboration from all stakeholders within the brain tumor community, so to have the ability to reconcile clinical practices and surveillance requirements.

Keywords: CBTRUS; brain tumors; epidemiology; histology.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Workflow of alignment of CBTRUS histology with groupings.
Fig. 2
Fig. 2
Changes in histology codes between categories, CBTRUS Statistical Report: US Cancer Statistics-NPCR and SEER, 2014–2018.
Fig. 3
Fig. 3
Incidence differences between schemes by histology, CBTRUS Statistical Report: US Cancer Statistics—NPCR and SEER, 2014–2018.
Fig. 4
Fig. 4
Survival differences between schemes by histology, CBTRUS Statistical Report: US Cancer Statistics—NPCR, 2001–2017.

References

    1. Ostrom Q, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous (CNS) tumors diagnosed in the United States in 2014-2018. Neuro Oncol. 2021; 23(12 Suppl 2):iii1–iii105. - PMC - PubMed
    1. Kleihues P, Cavenee W, eds. Tumours of the Nervous System: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2000.
    1. Louis D, Wiestler O, Cavanee W, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007.
    1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2016.
    1. Louis DN, Perry A, Wesseling P, et al. . The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021; 23(8):1231–1251. - PMC - PubMed